EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Ying-Qin Zhu, Yue Huang, Yin-Hao Shi, Chen-Song Huang, Guang-Yin Zhao, Zhi-De Liu, Ming-Jian Ma, Jing-Yuan Ye, Xiang Xu, Qi Liu, Xi-Tai Huang, Jie-Qin Wang und 2 weitere

Advanced Science · 2024

DOI: 10.1002/advs.202406714 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Ying-Qin Zhu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China. Hauptthemen laut MEDLINE: Deoxycytidine, Gemcitabine, Carcinoma, Pancreatic Ductal, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangzhou Science and Technology Program Project, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a dismal prognosis. Gemcitabine‐based chemotherapy has emerged as a first‐line treatment for PDAC. However, the development of gemcitabine resistance often results in therapeutic failure. In order to uncover the underlying mechanisms of gemcitabine resistance, gemcitabine‐resistant PDAC cell lines and patient‐derived xenograft (PDX) models are established and subjected to RNA sequencing. It is found that CMTM6 is closely related to gemcitabine resistance in PDAC. Multi‐omics analysis revealed that EP300‐mediated H3K27ac modification is involved in the transcriptional activation of CMTM6, which maintains IGF2BP1 expression by preventing its ubiquitination. The m 6 A reader IGF2BP1 stabilizes the EP300 and MYC mRNAs by recognizing m 6 A modifications, forming a positive feedback loop that enhances tumor stemness and ultimately contributes to PDAC resistance. The combined application of the EP300 inhibitor inobrodib and gemcitabine exerts a synergistic effect on PDAC. Overall, these findings reveal that the EP300–CMTM6–IGF2BP1 positive feedback loop facilitates gemcitabine resistance via epigenetic reprogramming and the combined use of inobrodib and gemcitabine represents a promising strategy for overcoming chemoresistance in PDAC, warranting further investigation in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineGemcitabineCarcinoma, Pancreatic DuctalDrug Resistance, NeoplasmPancreatic NeoplasmsRNA-Binding ProteinsEpigenesis, GeneticE1A-Associated p300 ProteinHumansMiceAnimalsFeedback, PhysiologicalCell Line, TumorAntimetabolites, AntineoplasticDisease Models, Animal

Stichwörter der Autor:innen

CMTM6N6‐methyladenosinechemoresistanceepigenetic modificationpancreatic ductal adenocarcinoma

Substanzen

DeoxycytidineGemcitabineRNA-Binding ProteinsE1A-Associated p300 ProteinIGF2BP1 protein, humanEP300 protein, humanAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.
  • Department of Medical Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, 510220, China.
  • Department of Animal Experiment Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.
  • Department of Pediatric Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, 510623, China.

ORCID-Profile: Xiao-Yu Yin

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Science and Technology Program Project
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Zhu, Y. Q., Huang, Y., Shi, Y. H., Huang, C. S., Zhao, G. Y., Liu, Z. D., Ma, M. J., Ye, J. Y., Xu, X., Liu, Q., Huang, X. T., Wang, J. Q., Xu, Q. C., & Yin, X. Y. (2024). Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Advanced Science. https://doi.org/10.1002/advs.202406714

Vancouver

Zhu YQ, Huang Y, Shi YH, Huang CS, Zhao GY, Liu ZD, et al. Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Advanced Science. 2024. doi:10.1002/advs.202406714

BibTeX
@article{Zhu2024,
  author = {Zhu, Ying-Qin and Huang, Yue and Shi, Yin-Hao and Huang, Chen-Song and Zhao, Guang-Yin and Liu, Zhi-De and Ma, Ming-Jian and Ye, Jing-Yuan and Xu, Xiang and Liu, Qi and Huang, Xi-Tai and Wang, Jie-Qin and Xu, Qiong-Cong and Yin, Xiao-Yu},
  title = {Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202406714}
}
Kostenlos starten →